FERRARI, Roberto
 Distribuzione geografica
Continente #
NA - Nord America 39.445
EU - Europa 11.131
AS - Asia 9.906
SA - Sud America 810
AF - Africa 89
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 17
Totale 61.432
Nazione #
US - Stati Uniti d'America 39.306
SG - Singapore 3.951
CN - Cina 3.621
IT - Italia 3.340
UA - Ucraina 2.403
DE - Germania 1.541
TR - Turchia 1.466
GB - Regno Unito 1.062
BR - Brasile 700
SE - Svezia 697
FI - Finlandia 663
PL - Polonia 491
FR - Francia 230
ID - Indonesia 224
VN - Vietnam 143
BE - Belgio 117
NL - Olanda 108
HK - Hong Kong 98
CA - Canada 89
RU - Federazione Russa 83
IN - India 78
AT - Austria 53
CZ - Repubblica Ceca 50
ES - Italia 48
CH - Svizzera 39
IQ - Iraq 36
LT - Lituania 32
CO - Colombia 31
MX - Messico 29
PK - Pakistan 29
IE - Irlanda 27
JP - Giappone 27
KR - Corea 25
AU - Australia 22
EG - Egitto 22
IR - Iran 21
LK - Sri Lanka 21
AR - Argentina 20
GE - Georgia 18
ZA - Sudafrica 18
RO - Romania 17
UZ - Uzbekistan 17
BD - Bangladesh 16
EC - Ecuador 16
AL - Albania 15
IL - Israele 13
EU - Europa 12
HR - Croazia 12
MA - Marocco 12
VE - Venezuela 12
BG - Bulgaria 11
HU - Ungheria 11
NZ - Nuova Zelanda 11
PE - Perù 11
PT - Portogallo 11
RS - Serbia 11
CL - Cile 10
GR - Grecia 10
TH - Thailandia 10
TW - Taiwan 10
JO - Giordania 9
NO - Norvegia 9
DK - Danimarca 8
PH - Filippine 8
SA - Arabia Saudita 8
TN - Tunisia 8
KG - Kirghizistan 6
MY - Malesia 6
PY - Paraguay 6
SK - Slovacchia (Repubblica Slovacca) 6
AE - Emirati Arabi Uniti 5
KE - Kenya 5
MD - Moldavia 5
MK - Macedonia 5
DZ - Algeria 4
JM - Giamaica 4
KZ - Kazakistan 4
LU - Lussemburgo 4
SI - Slovenia 4
SN - Senegal 4
YE - Yemen 4
AM - Armenia 3
AZ - Azerbaigian 3
BO - Bolivia 3
CU - Cuba 3
CY - Cipro 3
ET - Etiopia 3
MV - Maldive 3
NI - Nicaragua 3
PA - Panama 3
XK - ???statistics.table.value.countryCode.XK??? 3
BN - Brunei Darussalam 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CM - Camerun 2
CR - Costa Rica 2
GH - Ghana 2
KW - Kuwait 2
LB - Libano 2
NP - Nepal 2
Totale 61.397
Città #
Fairfield 5.337
Woodbridge 5.000
Houston 3.146
Jacksonville 2.703
Ashburn 2.665
Chandler 2.389
Ann Arbor 2.106
Seattle 2.089
Wilmington 1.864
Cambridge 1.776
Santa Clara 1.615
Singapore 1.556
Izmir 954
Nanjing 869
Princeton 751
Beijing 564
San Diego 477
Warsaw 472
Boardman 407
Milan 350
Ferrara 335
Shenyang 260
Shanghai 256
Nanchang 244
New York 233
Jakarta 210
Los Angeles 199
Helsinki 156
Falls Church 155
Rome 154
Hebei 147
Changsha 145
Jiaxing 143
Bremen 134
Redwood City 132
Tianjin 131
Munich 128
London 123
San Mateo 121
Mountain View 119
Dong Ket 118
Brussels 111
Addison 107
Jinan 97
Hong Kong 85
Zhengzhou 83
Norwalk 82
Dearborn 80
Naples 67
Ningbo 65
Bologna 63
Kunming 62
Washington 59
Verona 56
Des Moines 53
Guangzhou 52
Orange 51
Philadelphia 49
Falkenstein 47
Taizhou 45
São Paulo 44
Napoli 43
Nuremberg 40
Indiana 38
Chicago 37
Tappahannock 35
Turin 33
Florence 31
Council Bluffs 30
Ottawa 30
Auburn Hills 28
Hangzhou 27
Redmond 27
Frankfurt am Main 26
Changchun 24
Padova 24
Brno 23
Kilburn 23
Toronto 23
Bari 22
Lanzhou 22
Vienna 22
Belo Horizonte 20
Palermo 20
Catania 19
Augusta 18
Rio de Janeiro 18
Hounslow 17
Leawood 17
Olomouc 17
Tashkent 17
Tbilisi 17
Dublin 16
Torino 16
San Francisco 15
Tokyo 15
Curitiba 14
Genova 14
Pisa 14
Porto Alegre 14
Totale 42.997
Nome #
IL METABOLISMO DEL MIOCARDIO ISCHEMICO IBERNATO E STORDITO: DIFFERENZA TRA NECROSI E APOPTOSI 1.749
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD 349
Il lungo cammino degli inibitori dell'enzima di conversione dell'angiotensina nella lotta per le malattie cardiovascolari 334
A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial 282
Physical activity intervention for elderly patients with reduced physical performance after acute coronary syndrome (HULK study): Rationale and design of a randomized clinical trial 282
Valutazione ecocardiografica dell'insufficienza mitralica nella prospettiva della riparazione valvolare 269
Scompenso cardiaco con frazione di eiezione intermedia. Alla ricerca della Terra di Mezzo? 236
Left ventricular ejection fraction and heart failure: an indissoluble marriage? 236
The Notch pathway: a novel therapeutic target for cardiovascular diseases? 230
1,3,8-Triazaspiro compounds and their use as medicaments for the treatment of reperfusion injury. 214
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease 210
Demographic and clinical characteristics of patients with stable coronary artery disease: results from the CLARIFY registry in Spain 208
null 206
Estrogen receptor β-dependent Notch1 activation protects vascular endothelium against tumor necrosis factor α (TNFα)-induced apoptosis 205
Distinct gene expression profiles associated with Notch ligands Delta-like 4 and Jagged1 in plaque material from peripheral artery disease patients: A pilot study 202
Polar plot maps by parametric strain echocardiography allow accurate evaluation of non-viable transmural scar tissue in ischaemic heart disease 183
Mitochondrial permeability transition involves dissociation of F1FO ATP synthase dimers and C-ring conformation 182
Fo ATP synthase C subunit serum levels in patients with ST-segment Elevation Myocardial Infarction: Preliminary findings 177
17β-Estradiol Enhances Signalling Mediated by VEGF-A-Delta-Like Ligand 4-Notch1 Axis in Human Endothelial Cells 174
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma 174
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) 173
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure 168
CANCER THERAPY-INDUCED CARDIOTOXICITY: ROLE OF ULTRASOUND DEFORMATION IMAGING AS AN AID TO EARLY DIAGNOSIS 167
2014 ESC guidelines on the diagnosis and treatment of aortic diseases 166
Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile 165
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 163
Effects of temperature on myocardial calcium homeostasis and mitochondrial function during ischemia and reperfusion. 162
Cardiac resynchronization therapy guided by multimodality cardiac imaging 161
The role of Notch pathway in cardiovascular diseases. 160
Factor XI rs2036914 gene polymorphism and occurrence of adverse events after percutaneous coronary intervention. A prospective evaluation. 159
Heart failure with preserved ejection fraction: uncertainties and dilemmas 159
Poor response to clopidogrel: current and future options for its management 159
Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients 159
Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis 156
Discovery of Novel 1,3,8-Triazaspiro[4.5]decane Derivatives That Target the c Subunit of F1/FO-Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction 155
Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL 154
The frailty in elderly patients receiving cardiac interventional procedures (FRASER) program: rational and design of a multicenter prospective study 153
Kounis-Zavras syndrome presenting with ventricular arrhythmias and cardiogenic shock 152
2013 ESC guidelines on the management of stable coronary artery disease 151
Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients 151
The role of notch in the cardiovascular system: potential adverse effects of investigational notch inhibitors 151
Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. 148
Uric acid and coronary artery disease: An elusive link deserving further attention 148
Left Ventricular Lead Position Guided by Parametric Strain Echocardiography Improves Response to Cardiac Resynchronization Therapy 148
KRIT1 deficiency promotes aortic endothelial dysfunction 148
EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT) 147
Medical and interventional management of patients with severe thrombocytopenia undergoing percutaneous coronary intervention 146
Short Physical Performance Battery and all-cause mortality: Systematic review and meta-analysis 146
Predischarge screening for chronic obstructive pulmonary disease in patients with acute coronary syndrome and smoking history 145
Antiplatelet Treatment Reduces All-Cause Mortality in COPD Patients: A Systematic Review and Meta-Analysis 144
Factor XIII-A dynamics in acute myocardial infarction: a novel prognostic biomarker? 142
Fractional flow reserve evaluation and chronic kidney disease: Analysis from a multicenter Italian registry (the FREAK study) 141
Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: Analysis of the CLARIFY registry 140
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions 140
Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis 139
Mutation Load of Multiple Ion Channel Gene Mutations in Brugada Syndrome 139
Tailored Medical and Interventional Therapy Against Recurrent Stent Thrombosis After Drug-Eluting Stenting 138
Can we improve myocardial protection during ischaemic injury? 138
Ticagrelor improves endothelial function by decreasing circulating Epidermal Growth Factor (EGF) 137
Prolonged propionyl-L-carnitine pre-treatment of rabbit: biochemical, hemodynamic and electrophysiological effects on myocardium. 136
Individualized angiotensin-converting enzyme (ACE)-inhibitor therapy in stable coronary artery disease based on clinical and pharmacogenetic determinants: The PERindopril GENEtic (PERGENE) risk model 136
Cardiovascular complications of radiation therapy for thoracic malignancies: The role for non-invasive imaging for detection of cardiovascular disease 135
Reperfusion Damage - A Story of Success, Failure, and Hope 135
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes 134
Abnormalities of left ventricular function in asymptomatic patients with systemic sclerosis using doppler measures of myocardial strain. 134
A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals 134
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes (Am Journal of Cardiovasc Drugs (2011) 11:3 (189-98)) 133
A Clinical Case of Catecholaminergic Polymorphic Ventricular Tachycardia: The Clinical Suspicious and the Need of Genetics 133
The assessment of scales of frailty and physical performance improves prediction of major adverse cardiac events in older adults with acute coronary syndrome 133
The in vitro effects of verbascoside on human platelet aggregation 132
Coronary artery disease: Use of ACE inhibitors in stable CAD - What is the truth? 132
Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients with ST-Segment-Elevation Myocardial Infarction and Multivessel Disease 132
In Vitro Characterization of Circulating Endothelial Progenitor Cells Isolated from Patients with Acute Coronary Syndrome 131
Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study 131
Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials 131
Grip strength predicts cardiac adverse events in patients with cardiac disorders: An individual patient pooled meta-analysis 131
Nutritional status and all-cause mortality in older adults with acute coronary syndrome 131
Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE 130
Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention 129
RESTING HEART RATE IN CARDIOVASCULAR DISEASE 128
Is stunning an important component of preconditioning? 128
Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting 128
Time course of human atrial natriuretic factor release during cardiopulmonary bypass in mitral valve and coronary artery diseased patients. 127
Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - Results from EUROPA 127
Current views on anthracycline cardiotoxicity 127
High-dose BoluS TiRofibAn and Sirolimus eluting STEnt versus abiciximab and bare metal stent in acute MYocardial infarction (STRATEGY) study - Protocol design and demography of the first 100 patients 126
Not just numbers, but years of science: Putting the ACE inhibitor—ARB meta-analyses into context 126
Attualità e nuove prospettive in tema di cardiogenetica 126
Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: An analysis from the SIGNIFY study 125
Appropriateness of Prescriptions of Recommended Treatments in Organisation for Economic Co-operation and Development Health Systems: Findings Based on the Long-Term Registry of the European Society of Cardiology on Heart Failure 125
Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis 125
EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot) 125
Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial 125
Comparison of Verapamil versus Heparin as Adjunctive Treatment for Transradial Coronary Procedures: The VERMUT Study 125
Long-Term Effect of Perindopril on Coronary Atherosclerosis Progression (from the PERindopril's Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study) 124
Current role of echocardiography in cardiac resynchronization therapy 124
Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial 123
181 QUESTIONS & ANSWERS IN HEART FAILURE Heart failure 181 Questions & Answers. 123
Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: Findings from the international prospective CLARIFY registry 123
Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry 123
Totale 17.306
Categoria #
all - tutte 309.912
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 4.657
Totale 314.569


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.979 0 0 0 0 0 0 0 0 0 1.199 488 292
2020/20218.376 681 744 515 930 363 913 316 1.061 254 1.119 996 484
2021/20227.070 323 777 577 273 413 357 359 366 296 505 753 2.071
2022/20236.078 715 190 226 668 982 900 219 634 840 60 397 247
2023/20243.481 359 433 210 120 238 490 152 206 77 160 153 883
2024/20258.683 303 307 1.107 466 1.429 1.036 462 840 2.357 376 0 0
Totale 62.417